These will be the first human trials to assess the effectiveness of a ‘prime-boost’ vaccine using GenVec’s adenovector technology as a potential therapy for patients infected with HIV. The randomized, placebo-controlled study will measure safety and immunogenicity of the vaccine in 15 HIV positive patients.
The trial will combine two components, a DNA prime vaccine and GenVec’s adenovector-based technology used in the boost vaccine. The adenovector-based boost vaccine was developed using the company’s proprietary technology and 293-ORF6 cell line. Patients in the study will be treated with the first vaccine (known as DNA prime) followed by a booster with the second vaccine (known as rAD5 boost), and will be evaluated for 48 weeks.
The clinical trial will be conducted by the Vaccine Research Center as part of a broad effort to test HIV vaccines based on GenVec’s adenovector delivery technology and cell line.